Patient Related Outcome Measures | 2019

Lubiprostone in the treatment of chronic idiopathic constipation: an update on health-related quality of life and patient-reported outcomes

 
 
 

Abstract


Chronic idiopathic constipation, if inadequately treated, can be bothersome with a detrimental effect on patients’ quality of life (QOL). This may also result in frequent health care visits, increasing the burden of this ailment’s medical cost. Management strategies, focused on lifestyle changes, include increased exercise, a high-fiber diet, and toilet training. Pharmacologic options include fiber supplementation, laxatives, serotonergic agents, and prosecretory agents such as lubiprostone. In this review, we were able to conclude that lubiprostone, when used for chronic idiopathic constipation, has a significantly beneficial effect on both patients’ symptoms and their QOL. In multiple randomized controlled trials, it has been found to have increased the number of spontaneous bowel movements at different time endpoints. Corresponding improvements were also observed for abdominal bloating, discomfort, stool frequency, and straining symptoms among patients.

Volume 10
Pages 43 - 47
DOI 10.2147/PROM.S157905
Language English
Journal Patient Related Outcome Measures

Full Text